The Filings Report

Halozyme Therapeutics, Inc.

HALONasdaqCIK 1159036Healthcare / Biotechnologyfiscal year ends December65 quarters since 2010

Revenue, Q2 FY2026
$481M
+47.7% on Q2 FY2025
Net income
$230M
+39.2% on Q2 FY2025
Free cash flow
$237M
+141.2% on Q2 FY2025
Diluted EPS
$1.90
+42.9% on Q2 FY2025
Revenue, TTM
$1.7B
trailing four quarters
Net margin, TTM
24.9%
net income $414M
Free cash flow, TTM
$806M
$819M less $12M capex
Cash and equivalents
$163M
long-term debt $1.9B, Jun 30, 2026
Shares, 12-month change
−3.0%
113M shares, Jun 30, 2026, split-adjusted
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$14.6B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 6, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Halozyme Therapeutics, Inc. reported revenue of $481M, +47.7% on Q2 FY2025, and net income of $230M (+39.2%). Operating margin was 59.8%. Free cash flow, operating cash flow less capital expenditures, was $237M ($241M less $4M). Diluted earnings per share were $1.90.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 6, 2026.

Revenue and net incomeRevenueNet income
−$200M$0$200M$400M$600MQ3'22, Revenue: $209MQ3'22, Net income: $62MQ3'22Q4'22, Revenue: $181MQ4'22, Net income: $58MQ4'22Q1'23, Revenue: $162MQ1'23, Net income: $40MQ1'23Q2'23, Revenue: $221MQ2'23, Net income: $75MQ2'23Q3'23, Revenue: $216MQ3'23, Net income: $82MQ3'23Q4'23, Revenue: $230MQ4'23, Net income: $85MQ4'23Q1'24, Revenue: $196MQ1'24, Net income: $77MQ1'24Q2'24, Revenue: $231MQ2'24, Net income: $93MQ2'24Q3'24, Revenue: $290MQ3'24, Net income: $137MQ3'24Q4'24, Revenue: $298MQ4'24, Net income: $137MQ4'24Q1'25, Revenue: $265MQ1'25, Net income: $118MQ1'25Q2'25, Revenue: $326MQ2'25, Net income: $165MQ2'25Q3'25, Revenue: $354MQ3'25, Net income: $175MQ3'25Q4'25, Revenue: $452MQ4'25, Net income: −$142MQ4'25Q1'26, Revenue: $377MQ1'26, Net income: $150MQ1'26Q2'26, Revenue: $481MQ2'26, Net income: $230MQ2'26−$200M$0$200M$400M$600MQ3'22, Revenue: $209MQ3'22, Net income: $62MQ4'22, Revenue: $181MQ4'22, Net income: $58MQ4'22Q1'23, Revenue: $162MQ1'23, Net income: $40MQ2'23, Revenue: $221MQ2'23, Net income: $75MQ2'23Q3'23, Revenue: $216MQ3'23, Net income: $82MQ4'23, Revenue: $230MQ4'23, Net income: $85MQ4'23Q1'24, Revenue: $196MQ1'24, Net income: $77MQ2'24, Revenue: $231MQ2'24, Net income: $93MQ2'24Q3'24, Revenue: $290MQ3'24, Net income: $137MQ4'24, Revenue: $298MQ4'24, Net income: $137MQ4'24Q1'25, Revenue: $265MQ1'25, Net income: $118MQ2'25, Revenue: $326MQ2'25, Net income: $165MQ2'25Q3'25, Revenue: $354MQ3'25, Net income: $175MQ4'25, Revenue: $452MQ4'25, Net income: −$142MQ4'25Q1'26, Revenue: $377MQ1'26, Net income: $150MQ2'26, Revenue: $481MQ2'26, Net income: $230MQ2'26

Net income losses drawn in red.

Free cash flow
$0$100M$200M$300MQ3'22, Free cash flow: $69MQ3'22Q4'22, Free cash flow: $80MQ4'22Q1'23, Free cash flow: $76MQ1'23Q2'23, Free cash flow: $68MQ2'23Q3'23, Free cash flow: $129MQ3'23Q4'23, Free cash flow: $100MQ4'23Q1'24, Free cash flow: $126MQ1'24Q2'24, Free cash flow: $53MQ2'24Q3'24, Free cash flow: $114MQ3'24Q4'24, Free cash flow: $175MQ4'24Q1'25, Free cash flow: $153MQ1'25Q2'25, Free cash flow: $98MQ2'25Q3'25, Free cash flow: $176MQ3'25Q4'25, Free cash flow: $218MQ4'25Q1'26, Free cash flow: $176MQ1'26Q2'26, Free cash flow: $237MQ2'26$0$100M$200M$300MQ3'22, Free cash flow: $69MQ4'22, Free cash flow: $80MQ4'22Q1'23, Free cash flow: $76MQ2'23, Free cash flow: $68MQ2'23Q3'23, Free cash flow: $129MQ4'23, Free cash flow: $100MQ4'23Q1'24, Free cash flow: $126MQ2'24, Free cash flow: $53MQ2'24Q3'24, Free cash flow: $114MQ4'24, Free cash flow: $175MQ4'24Q1'25, Free cash flow: $153MQ2'25, Free cash flow: $98MQ2'25Q3'25, Free cash flow: $176MQ4'25, Free cash flow: $218MQ4'25Q1'26, Free cash flow: $176MQ2'26, Free cash flow: $237MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3BQ3'22, Cash and equivalents: $147MQ3'22, Long-term debt: $1.5BQ3'22Q4'22, Cash and equivalents: $234MQ4'22, Long-term debt: $1.5BQ4'22Q1'23, Cash and equivalents: $96MQ1'23, Long-term debt: $1.5BQ1'23Q2'23, Cash and equivalents: $221MQ2'23, Long-term debt: $1.5BQ2'23Q3'23, Cash and equivalents: $274MQ3'23, Long-term debt: $1.5BQ3'23Q4'23, Cash and equivalents: $118MQ4'23, Long-term debt: $1.5BQ4'23Q1'24, Cash and equivalents: $165MQ1'24, Long-term debt: $1.5BQ1'24Q2'24, Cash and equivalents: $188MQ2'24, Long-term debt: $1.5BQ2'24Q3'24, Cash and equivalents: $154MQ3'24, Long-term debt: $1.5BQ3'24Q4'24, Cash and equivalents: $116MQ4'24, Long-term debt: $1.5BQ4'24Q1'25, Cash and equivalents: $176MQ1'25, Long-term debt: $1.5BQ1'25Q2'25, Cash and equivalents: $62MQ2'25, Long-term debt: $1.5BQ2'25Q3'25, Cash and equivalents: $420MQ3'25, Long-term debt: $800MQ3'25Q4'25, Cash and equivalents: $134MQ4'25, Long-term debt: $2.1BQ4'25Q1'26, Cash and equivalents: $310MQ1'26, Long-term debt: $1.9BQ1'26Q2'26, Cash and equivalents: $163MQ2'26, Long-term debt: $1.9BQ2'26$0$1B$2B$3BQ3'22, Cash and equivalents: $147MQ3'22, Long-term debt: $1.5BQ4'22, Cash and equivalents: $234MQ4'22, Long-term debt: $1.5BQ4'22Q1'23, Cash and equivalents: $96MQ1'23, Long-term debt: $1.5BQ2'23, Cash and equivalents: $221MQ2'23, Long-term debt: $1.5BQ2'23Q3'23, Cash and equivalents: $274MQ3'23, Long-term debt: $1.5BQ4'23, Cash and equivalents: $118MQ4'23, Long-term debt: $1.5BQ4'23Q1'24, Cash and equivalents: $165MQ1'24, Long-term debt: $1.5BQ2'24, Cash and equivalents: $188MQ2'24, Long-term debt: $1.5BQ2'24Q3'24, Cash and equivalents: $154MQ3'24, Long-term debt: $1.5BQ4'24, Cash and equivalents: $116MQ4'24, Long-term debt: $1.5BQ4'24Q1'25, Cash and equivalents: $176MQ1'25, Long-term debt: $1.5BQ2'25, Cash and equivalents: $62MQ2'25, Long-term debt: $1.5BQ2'25Q3'25, Cash and equivalents: $420MQ3'25, Long-term debt: $800MQ4'25, Cash and equivalents: $134MQ4'25, Long-term debt: $2.1BQ4'25Q1'26, Cash and equivalents: $310MQ1'26, Long-term debt: $1.9BQ2'26, Cash and equivalents: $163MQ2'26, Long-term debt: $1.9BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 6, 2026.

Halozyme Therapeutics, Inc. income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 11, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue481377452354326265298290+47.7%
Cost of revenue7979795546484249+70.8%
Gross profit—————————
Research and development2826—1718152018+57.7%
Selling, general and administrative5758774642424241+37.0%
Operating income288185(93)218202142176163+42.1%
Other income (expense)31257776−58.8%
Pretax income285180(101)219205144178165+39.0%
Income tax5530414440264128+38.2%
Net income230150(142)175165118137137+39.2%
Diluted EPS ($)1.901.22—1.431.330.93—1.05+42.9%
Diluted shares (millions)121123—122124127—130—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 6, 2026.

Halozyme Therapeutics, Inc. balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 11, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents16331013442062176116154+163.7%
Short-term investments—————————
Total current assets9331,0038251,3291,1231,2621,0851,127−16.9%
Total assets2,5772,6732,5252,2212,0542,1972,0632,118+25.5%
Total current liabilities344363177837134150139109+156.5%
Long-term debt1,9381,9362,1438001,5091,5071,5061,504+28.4%
Total liabilities2,4342,4532,4771,7171,7211,7141,7001,665+41.4%
Stockholders’ equity14422049504333482364453−56.9%
Shares outstanding (millions)113119118118117123123127—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 6, 2026.

Halozyme Therapeutics, Inc. cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 11, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Nov 3, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow241180219179100154178115+141.6%
Capital expenditures44132132+167.0%
Free cash flow (CFO − capex)23717621817698153175114+141.2%
Depreciation and amortization54333333+66.7%
Share repurchases——039——2500—
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 17, 2026.

Income statement

Halozyme Therapeutics, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 22, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 20, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Mar 1, 2013FY2011ended Dec 31, 2011filed Mar 12, 2012FY2010ended Dec 31, 2010filed Aug 5, 2011FY2009ended Dec 31, 2009filed Aug 5, 2011
Revenue1,3971,015829660443268196152317147135755542561414
Cost of revenue2291591921398143461031————————
Gross profit—————————————————
Research and development—797667363414115015115193809770585257
Selling, general and administrative20715414914450467761544640363225181515
Operating income469551338268276144(68)(69)81(83)(27)(63)(80)(54)(20)(54)(58)
Other income (expense)21241611578310——0010
Pretax income467557348249249129(72)(80)62(102)(32)(68)—————
Income tax1501136747(154)001(1)100—————
Net income317444282202403129(72)(80)63(103)(32)(68)(83)(54)(20)(53)(58)
Diluted EPS ($)2.563.432.101.442.740.91(0.50)(0.56)0.45(0.81)(0.25)——————
Diluted shares (millions)124129134141147141144144139128127——————

Balance sheet

Halozyme Therapeutics, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 22, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 20, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Mar 1, 2013FY2011ended Dec 31, 2011filed Mar 12, 2012FY2010ended Dec 31, 2010filed Aug 5, 2011FY2009ended Dec 31, 2009filed Aug 5, 2011
Cash and equivalents1341161182341191481205816967436127100528367
Short-term investments———129622220301——————————
Total current assets8251,085746739926555543428510257172161951316489—
Total assets2,5252,0631,7331,8421,1045805664405202621821661021356691—
Total current liabilities1771391121311174218614913155622425191715—
Long-term debt2,1431,5061,4991,493787038335125199285050300——
Total liabilities2,4771,7001,6491,672—————————————
Stockholders’ equity493648417019715192249208(32)4341(20)4911207
Shares outstanding (millions)118123127135138135138145143130129127124113112——

Cash flow statement

Halozyme Therapeutics, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 22, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 20, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Mar 1, 2013FY2011ended Dec 31, 2011filed Mar 12, 2012FY2010ended Dec 31, 2010filed Aug 5, 2011FY2009ended Dec 31, 2009filed Aug 5, 2011
Operating cash flow65247938924029955(85)(49)134(50)(37)(48)(49)(64)(34)(45)(40)
Capital expenditures7111551345132121111
Free cash flow (CFO − capex)64546837323529853(89)(54)133(54)(39)(49)(52)(66)(35)(46)(42)
Depreciation and amortization11101163342222211121
Share repurchases34225040220035015020000————————
Dividends paid—————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$22M
39 sales by 3 insiders; officers and directors $22M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$48M
105 sales by 5 insiders; officers and directors $48M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 8, 2026Torley HelenPRESIDENT AND CEO, Directoroption exercise20,000$18.41$368K787,780Oct 8, 2026
Oct 8, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-14,810$108.18$520K782,970Oct 8, 2026
Oct 8, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-13,090$108.91$337K779,880Oct 8, 2026
Oct 8, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-111,900$110.00$1M767,980Oct 8, 2026
Oct 8, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-1200$110.51$22K767,780Oct 8, 2026
Oct 7, 2026Torley HelenPRESIDENT AND CEO, Directoroption exercise20,000$18.41$368K787,780Oct 8, 2026
Oct 7, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-18,600$111.03$955K779,180Oct 8, 2026
Oct 7, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-110,300$111.84$1M768,880Oct 8, 2026
Oct 7, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-1900$112.78$102K767,980Oct 8, 2026
Oct 7, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-1200$113.69$23K767,780Oct 8, 2026
Oct 6, 2026Torley HelenPRESIDENT AND CEO, Directoroption exercise20,000$18.41$368K787,780Oct 8, 2026
Oct 6, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-12,300$107.90$248K785,480Oct 8, 2026
Oct 6, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-16,000$109.33$656K779,480Oct 8, 2026
Oct 6, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-19,920$109.89$1M769,560Oct 8, 2026
Oct 6, 2026Torley HelenPRESIDENT AND CEO, Directoropen-market sale10b5-11,780$110.81$197K767,780Oct 8, 2026
Oct 1, 2026Daly James MDirectoraward1,169$0.00—1,169Oct 2, 2026
Oct 1, 2026Posard Matthew L.Directoropen-market sale10b5-1730$107.17$78K58,109Oct 2, 2026
Oct 1, 2026Posard Matthew L.Directoropen-market sale10b5-13,300$108.45$358K54,809Oct 2, 2026
Oct 1, 2026Posard Matthew L.Directoropen-market sale10b5-11,100$109.57$121K53,709Oct 2, 2026
Oct 1, 2026Posard Matthew L.Directoropen-market sale10b5-1100$110.04$11K53,609Oct 2, 2026
Sep 16, 2026Posard Matthew L.Directoropen-market sale10b5-13,100$106.13$329K74,735Sep 17, 2026
Sep 16, 2026Posard Matthew L.Directoropen-market sale10b5-13,000$106.83$320K71,735Sep 17, 2026
Sep 16, 2026Posard Matthew L.Directoropen-market sale10b5-18,896$108.04$961K62,839Sep 17, 2026
Sep 16, 2026Posard Matthew L.Directoropen-market sale10b5-14,000$108.99$436K58,839Sep 17, 2026
Sep 11, 2026Torley HelenPRESIDENT AND CEO, Directoroption exercise20,000$18.41$368K787,780Sep 11, 2026

Full insider history for Halozyme Therapeutics, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
HALOZYME THERAPEUTICS, INC., CIK 1159036 on EDGAR
Extract generated
November 4, 2026
Withheld
5 line-years whose four quarters do not sum to the filed year: depreciation amortization FY2014, net income FY2015, revenue FY2015, depreciation amortization FY2017, depreciation amortization FY2018
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/HALO.json